Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX
SNDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.58 - $25.07
Previous CloseN/A
Volume201.89K
Average Volume (3M)2.53M
Market Cap
$778.73M
Enterprise ValueN/A
Total Cash (Recent Filing)$512.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Aug 11, 2025EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding86,047,450
10 Day Avg. Volume3,655,781
30 Day Avg. Volume2,530,393
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)3.97
Price to Sales (P/S)0.00
P/FCF Ratio-3.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$33.56Price Target Upside270.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Market PositionManagement’s encouraging feedback and initial sales success suggest potential for Syndax’s use to expand into the larger NPM1m population.
Prescription And ReimbursementThe vast majority of prescriptions are reimbursed with 72% of managed care lives on formulary coverage at the end of March.
Sales PerformanceRevuforj outperformed in its first full quarter with $20M in sales, overshadowing concerns about GAAP EPS.
Bears Say
Competitive MarketDespite uncertainties in the competitive market, there is a belief that market share will be more evenly split, suggesting confidence in Syndax’s position.
Expense GuidanceR&D and SG&A expense guidance for 2025 is below pre-earnings consensus, indicating potential cost efficiency.
Long-Term OutlookNiktimvo’s longer-term outlook remains uncertain as use is expected to be reserved in transplant centers.
---
Ownership Overview
1.32% Insiders
16.82% Mutual Funds
2.37% Other Institutional Investors
63.49% Public Companies and Individual Investors
SNDX FAQ
What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?
Syndax Pharmaceuticals Inc lowest stock price was $8.58 and its highest was $25.07 in the past 12 months.
What is Syndax Pharmaceuticals Inc’s market cap?
Syndax Pharmaceuticals Inc’s market cap is $778.73M.
When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?
Syndax Pharmaceuticals Inc’s upcoming earnings report date is Aug 11, 2025 which is in 84 days.
How were Syndax Pharmaceuticals Inc’s earnings last quarter?
Syndax Pharmaceuticals Inc released its earnings results on May 05, 2025. The company reported -$0.98 earnings per share for the quarter, beating the consensus estimate of -$1.252 by $0.272.
Is Syndax Pharmaceuticals Inc overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc pay dividends?
Syndax Pharmaceuticals Inc does not currently pay dividends.
What is Syndax Pharmaceuticals Inc’s EPS estimate?
Syndax Pharmaceuticals Inc’s EPS estimate is -0.99.
How many shares outstanding does Syndax Pharmaceuticals Inc have?
Syndax Pharmaceuticals Inc has 86,047,450 shares outstanding.
What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc reported an EPS of -$0.98 in its last earnings report, beating expectations of -$1.252. Following the earnings report the stock price went down -21.592%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in SNDX
---
Syndax Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.56 (270.83% Upside)
$33.56 (270.83% Upside)
Blogger Sentiment
Bullish
SNDX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 9.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $336.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.73%
12-Months-Change
Fundamentals
Return on Equity
-93.70%
Trailing 12-Months
Asset Growth
17.99%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer treatment. The company operates primarily in the biotechnology sector, with a commitment to discovering, developing, and delivering novel therapies that address unmet needs in oncology. Its core products include a pipeline of drug candidates designed to enhance the effectiveness of existing cancer treatments and improve patient outcomes.
---
SNDX Company Deck
---
SNDX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong initial sales of newly launched products and promising developments in the pipeline. While there are some uncertainties regarding market size and reimbursement, the overall outlook is optimistic due to financial stability and strategic advancements.Read More>---
SNDX Stock 12 Month Forecast
Average Price Target
$33.56
▲(270.83% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Viridian Therapeutics
―
Evolent Health
―
Vir Biotechnology
―
Structure Therapeutics, Inc. Sponsored ADR
―
---